The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
New‐onset autoimmune phenomena post‐COVID‐19 vaccination
Open accessAbstract
Coronavirus disease 2019 (COVID‐19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has led to an unprecedented setback for global economy and health. Vaccination is one of the most effective interventions to substantially reduce severe disease and death due to SARS‐CoV‐2 infection. Vaccination programmes are being rolled out globally, but most of these vaccines have been approved without extensive studies on their side‐effects and efficacy. Recently, new‐onset autoimmune phenomena after COVID‐19 vaccination have been reported increasingly (e.g. immune thrombotic thrombocytopenia, autoimmune liver diseases, Guillain–Barré syndrome, IgA nephropathy, rheumatoid arthritis and systemic lupus erythematosus). Molecular mimicry, the production of particular autoantibodies and the role of certain vaccine adjuvants seem to be substantial contributors to autoimmune phenomena. However, whether the association between COVID‐19 vaccine and autoimmune manifestations is coincidental or causal remains to be elucidated. Here, we summarize the emerging evidence about autoimmune manifestations occurring in response to certain COVID‐19 vaccines. Although information pertaining to the risk of autoimmune disease as a consequence of vaccination is controversial, we merely propose our current understanding of autoimmune manifestations associated with COVID‐19 vaccine. In fact, we do not aim to disavow the overwhelming benefits of mass COVID‐19 vaccination in preventing COVID‐19 morbidity and mortality. These reports could help guide clinical assessment and management of autoimmune manifestations after COVID‐19 vaccination.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · cited 1×
“Johnson & Johnson and AstraZeneca), elicit robust humoral responses and have shown safety in the majority of populations vaccinated [12].”
BackgroundThrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104840 · Cited by 2,259 · cited 2×
“Among these 11 patients, nine cases had CVST, three cases had SVT, three cases had pulmonary embolism, and four cases had other blood clots [59].”
BackgroundA global database of COVID-19 vaccinations
Mathieu, E., Ritchie, H., Ortiz-Ospina, E., Roser, M., Hasell, J., Appel, C., Giattino, C., & Rodés-Guirao, L. (2021) · Nature Human Behaviour · doi:10.1038/s41562-021-01122-8 · Cited by 1,974 · cited 1×
“As of 6 September 2021, 40·4% of the population worldwide have been given at least one dose of a COVID19 vaccine, and 5·45 billion doses have been administered globally [11].”
BackgroundThrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Schultz, N. H., Sørvoll, I. H., Michelsen, A. E., Munthe, L. A., Lund-Johansen, F., Ahlen, M. T., Wiedmann, M., Aamodt, A.-H., Skattør, T. H., Tjønnfjord, G. E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2104882 · Cited by 1,452
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
Scully, M., Singh, D., Lown, R., Poles, A., Solomon, T., Levi, M., Goldblatt, D., Kotoucek, P., Thomas, W., & Lester, W. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105385 · Cited by 964
Diagnosis and management of Guillain–Barré syndrome in ten steps
Leonhard, S. E., Mandarakas, M. R., Gondim, F. A. A., Bateman, K., Ferreira, M. L. B., Cornblath, D. R., van Doorn, P. A., Dourado, M. E., Hughes, R. A. C., Islam, B., et al. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0250-9 · Cited by 910
McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.03.092 · Cited by 808
COVID-19 vaccines: modes of immune activation and future challenges
Teijaro, J. R., & Farber, D. L. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00526-x · Cited by 701
Ndeupen, S., Qin, Z., Jacobsen, S., Bouteau, A., Estanbouli, H., & Igyártó, B. Z. (2021) · iScience · doi:10.1016/j.isci.2021.103479 · Cited by 678
How COVID-19 induces cytokine storm with high mortality
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020) · Inflammation and Regeneration · doi:10.1186/s41232-020-00146-3 · Cited by 663
Molecular mimicry and immune‐mediated diseases
Oldstone, M. B. A. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.13.1255 · Cited by 599
Vojdani, A., & Kharrazian, D. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108480 · Cited by 588
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Ehrenfeld, M., Tincani, A., Andreoli, L., Cattalini, M., Greenbaum, A., Kanduc, D., Alijotas-Reig, J., Zinserling, V., Semenova, N., Amital, H., et al. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102597 · Cited by 559
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military
Montgomery, J., Ryan, M., Engler, R., Hoffman, D., McClenathan, B., Collins, L., Loran, D., Hrncir, D., Herring, K., Platzer, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2833 · Cited by 536
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape
McCarthy, K. R., Rennick, L. J., Nambulli, S., Robinson-McCarthy, L. R., Bain, W. G., Haidar, G., & Duprex, W. P. (2021) · Science · doi:10.1126/science.abf6950 · Cited by 535
See, I., Su, J. R., Lale, A., Woo, E. J., Guh, A. Y., Shimabukuro, T. T., Streiff, M. B., Rao, A. K., Wheeler, A. P., Beavers, S. F., et al. (2021) · JAMA · doi:10.1001/jama.2021.7517 · Cited by 532
The SARS-CoV-2 as an instrumental trigger of autoimmunity
Dotan, A., Muller, S., Kanduc, D., David, P., Halpert, G., & Shoenfeld, Y. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102792 · Cited by 494
Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination
Muir, K.-L., Kallam, A., Koepsell, S. A., & Gundabolu, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2105869 · Cited by 412
Pottegård, A., Lund, L. C., Karlstad, Ø., Dahl, J., Andersen, M., Hallas, J., Lidegaard, Ø., Tapia, G., Gulseth, H. L., Ruiz, P. L.-D., et al. (2021) · BMJ · doi:10.1136/bmj.n1114 · Cited by 401
Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction
Segal, Y., & Shoenfeld, Y. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.151 · Cited by 395
Ndwandwe, D., & Wiysonge, C. S. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.07.003 · Cited by 381
Next-generation vaccine platforms for COVID-19
van Riel, D., & de Wit, E. (2020) · Nature Materials · doi:10.1038/s41563-020-0746-0 · Cited by 374
Vaccination and autoimmune disease: what is the evidence?
Wraith, D. C., Goldman, M., & Lambert, P.-H. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14802-7 · Cited by 362
SARS-CoV-2: virus dynamics and host response
Chen, Y., & Li, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30235-8 · Cited by 286
Self-citationKanduc, D., & Shoenfeld, Y. (2020) · Immunologic Research · doi:10.1007/s12026-020-09152-6 · Cited by 263
Role of the NLRP3 inflammasome in autoimmune diseases
Li, Z., Guo, J., & Bi, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110542 · Cited by 261
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow’s triad
Ahmed, S., Zimba, O., & Gasparyan, A. Y. (2020) · Clinical Rheumatology · doi:10.1007/s10067-020-05275-1 · Cited by 251
Simpson, C. R., Shi, T., Vasileiou, E., Katikireddi, S. V., Kerr, S., Moore, E., McCowan, C., Agrawal, U., Shah, S. A., Ritchie, L. D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01408-4 · Cited by 251
Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine
Waheed, S., Bayas, A., Hindi, F., Rizvi, Z., & Espinosa, P. S. (2021) · Cureus · doi:10.7759/cureus.13426 · Cited by 240
Othman, M., Labelle, A., Mazzetti, I., Elbatarny, H. S., & Lillicrap, D. (2007) · Blood · doi:10.1182/blood-2006-06-032524 · Cited by 220
Rosenblum, H. G., Hadler, S. C., Moulia, D., Shimabukuro, T. T., Su, J. R., Tepper, N. K., Ess, K. C., Woo, E. J., Mba-Jonas, A., Alimchandani, M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7032e4 · Cited by 207
Vera-Lastra, O., Ordinola Navarro, A., Cruz Domiguez, M. P., Medina, G., Sánchez Valadez, T. I., & Jara, L. J. (2021) · Thyroid · doi:10.1089/thy.2021.0142 · Cited by 202
Ramge, P., Unger, R. E., Oltrogge, J. B., Zenker, D., Begley, D., Kreuter, J., & Von Briesen, H. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00078.x · Cited by 197
Bril, F., Al Diffalha, S., Dean, M., & Fettig, D. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.003 · Cited by 192
Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine
Maramattom, B. V., Krishnan, P., Paul, R., Padmanabhan, S., Cherukudal Vishnu Nampoothiri, S., Syed, A. A., & Mangat, H. S. (2021) · Annals of Neurology · doi:10.1002/ana.26143 · Cited by 174
Guillain–Barré Syndrome Variant Occurring after SARS‐CoV‐2 Vaccination
Allen, C. M., Ramsamy, S., Tarr, A. W., Tighe, P. J., Irving, W. L., Tănăsescu, R., & Evans, J. (2021) · Annals of Neurology · doi:10.1002/ana.26144 · Cited by 171
Bunders, M. J., & Altfeld, M. (2020) · Immunity · doi:10.1016/j.immuni.2020.08.003 · Cited by 163
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines
Risma, K., Edwards, K. M., Hummell, D. S., Little, F. F., Norton, A. E., Stallings, A. P., Wood, R. A., & Milner, J. D. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.04.002 · Cited by 162
Chen, R., Lan, Z., Ye, J., Pang, L., Liu, Y., Wu, W., Qin, X., Guo, Y., & Zhang, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.589095 · Cited by 161
Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., Su, J. R., Licata, C., Rosenblum, H. G., Myers, T. R., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7031e1 · Cited by 159
Allergic reactions to the first COVID‐19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdiş, C. A., & Novak, N. (2020) · Allergy · doi:10.1111/all.14711 · Cited by 157
Molecular mimicry and auto-immunity
Blank, M., Barzilai, O., & Shoenfeld, Y. (2007) · Clinical Reviews in Allergy & Immunology · doi:10.1007/bf02686087 · Cited by 153
Welsh, K. J., Baumblatt, J. A. G., Chege, W., Goud, R., & Nair, N. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.04.054 · Cited by 147
Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases
Perricone, C., Ceccarelli, F., Nesher, G., Borella, E., Odeh, Q., Conti, F., Shoenfeld, Y., & Valesini, G. (2014) · Immunologic Research · doi:10.1007/s12026-014-8597-x · Cited by 146
On the molecular determinants of the SARS-CoV-2 attack
Kanduc, D., & Shoenfeld, Y. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108426 · Cited by 144
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
Greinacher, A., Selleng, K., Mayerle, J. V., Palankar, R., Wesche, J., Reiche, S., Aebischer, A., Warkentin, T. E., Muenchhoff, M., Hellmuth, J. C., et al. (2021) · Blood · doi:10.1182/blood.2021012938 · Cited by 144
Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
Lai, K.-Y., Au, S.-Y., & Fong, K.-M. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2107227 · Cited by 137
Klimek, L., Novak, N., Cabanillas, B., Jutel, M., Bousquet, J. J., & Akdiş, C. A. (2021) · Allergy · doi:10.1111/all.14794 · Cited by 136
COVID-19 vaccine side effects: The positives about feeling bad
Sprent, J., & King, C. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj9256 · Cited by 129
COVID-19 challenges and its therapeutics
Rehman, S. U., Rehman, S. U., & Yoo, H. H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112015 · Cited by 129
Woo, E. J., Mba‐Jonas, A., Dimova, R. B., Alimchandani, M., Zinderman, C. E., & Nair, N. (2021) · JAMA · doi:10.1001/jama.2021.16496 · Cited by 126
Wack, S., Patton, T., & Ferris, L. K. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2021.07.054 · Cited by 120
Mehta, P. R., Mangion, S. A., Benger, M., Stanton, B. R., Czuprynska, J., Arya, R., & Sztriha, L. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.04.006 · Cited by 118
Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know
Arepally, G. M., & Ortel, T. L. (2021) · Blood · doi:10.1182/blood.2021012152 · Cited by 118
Autoimmune hepatitis triggered by SARS-CoV-2 vaccination
Vuille‐Lessard, É., Montani, M., Bosch, J., & Semmo, N. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102710 · Cited by 116
Patel, S. U., Khurram, R., Lakhani, A., & Quirk, B. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242956 · Cited by 113
Targeting inflammation and cytokine storm in COVID-19
Huang, Q., Wu, X., Zheng, X., Luo, S., Xu, S., & Weng, J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105051 · Cited by 111
Ghielmetti, M., Schaufelberger, H. D., Mieli‐Vergani, G., Cerny, A., Dayer, E., Vergani, D., & Beretta‐Piccoli, B. T. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102706 · Cited by 111
Guillain-Barré syndrome after COVID-19 vaccination
McKean, N., & Chircop, C. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-244125 · Cited by 110
Successful treatment of vaccine‐induced prothrombotic immune thrombocytopenia (VIPIT)
Thaler, J., Ay, C., Gleixner, K. V., Hauswirth, A. W., Cacioppo, F., Grafeneder, J., Quehenberger, P., Pabinger, I., & Knöbl, P. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15346 · Cited by 109
Viral Coagulopathy in Patients With COVID-19: Treatment and Care
Kipshidze, N., Dangas, G., White, C. J., Kipshidze, N. N., Siddiqui, F., Lattimer, C. R., Carter, C. A., & Fareed, J. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620936776 · Cited by 107
Sørvoll, I. H., Horvei, K. D., Ernstsen, S. L., Lægreid, I. J., Lund, S., Grønli, R. H., Olsen, M. K., Jacobsen, H. K., Eriksson, A., Halstensen, A. M., et al. (2021) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15352 · Cited by 103
Case of Guillain-Barré syndrome following COVID-19 vaccine
Hasan, T., Khan, M., Khan, F., & Hamza, G. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243629 · Cited by 99
Allergy to COVID-19 vaccines: A current update
Cabanillas, B., & Novak, N. (2021) · Allergology International · doi:10.1016/j.alit.2021.04.003 · Cited by 95
Auto-immune hepatitis following COVID vaccination
Rela, M., Jothimani, D. K., Vij, M., Rajakumar, A., & Rammohan, A. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102688 · Cited by 95
The mRNA COVID-19 vaccine – A rare trigger of autoimmune hepatitis?
McShane, C., Kiat, C., Rigby, J., & Crosbie, O. M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.044 · Cited by 90
Another case of autoimmune hepatitis after SARS-CoV-2 vaccination – still casualty?
Londoño, M., Gratacós‐Ginès, J., & Sáez‐Peñataro, J. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.004 · Cited by 89
Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine
Garcia-Grimshaw, M. A., Michel‐Chávez, A., Vera-Zertuche, J. M., Galnares‐Olalde, J. A., Hernández‐Vanegas, L. E., Figueroa-Cucurachi, M., Paredes-Ceballos, O., Reyes‐Terán, G., Carbajal‐Sandoval, G., Ceballos‐Liceaga, S. E., et al. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108818 · Cited by 88
Autoimmune phenomena following SARS-CoV-2 vaccination
Ishay, Y., Kenig, A., Tsemach-Toren, T., Amer, R., Rubin, L., Hershkovitz, Y., & Kharouf, F. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107970 · Cited by 87
A case of Graves' disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination
Patrizio, A., Ferrari, S. M., Antonelli, A., & Fallahi, P. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102738 · Cited by 87
On the relationship between human papilloma virus vaccine and autoimmune diseases
Pellegrino, P., Carnovale, C., Pozzi, M., Antoniazzi, S., Perrone, V., Salvati, D., Gentili, M., Brusadelli, T., Clementi, E., & Radice, S. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.054 · Cited by 86
Babamahmoodi, F., Saeedi, M., Alizadeh‐Navaei, R., Hedayatizadeh‐Omran, A., Mousavi, S. A., Ovaise, G., Kordi, S., Akbari, Z., Azordeh, M., Ahangarkani, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00963-7 · Cited by 85
Mechanisms of tissue injury in autoimmune liver diseases
Liaskou, E., Hirschfield, G. M., & Gershwin, M. E. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0439-3 · Cited by 81
Inflammasome-Mediated Immunogenicity of Clinical and Experimental Vaccine Adjuvants
Reinke, S., Thakur, A., Gartlan, C., Bezbradica, J. S., & Milicic, A. (2020) · Vaccines · doi:10.3390/vaccines8030554 · Cited by 78
Post-COVID-19 vaccine Guillain-Barré syndrome; first reported case from Qatar
Razok, A., Shams, A., Almeer, A., & Zahid, M. (2021) · Annals of Medicine and Surgery · doi:10.1016/j.amsu.2021.102540 · Cited by 77
Cherian, S., Paul, A., Ahmed, S., Alias, B., Manoj, M., Santhosh, A. K., Varghese, D. R., Narayanan, K. S., & Shenoy, P. D. (2021) · Rheumatology International · doi:10.1007/s00296-021-04917-0 · Cited by 77
Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine
Clayton‐Chubb, D., Schneider, D., Freeman, E., Kemp, W. W., & Roberts, S. K. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.06.014 · Cited by 69
Hepatitis A vaccine associated with autoimmune hepatitis
Berry, P., & Smith-Laing, G. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i15.2238 · Cited by 60
Autoimmunity roots of the thrombotic events after COVID-19 vaccination
Elrashdy, F., Tambuwala, M. M., Hassan, S. S., Adadi, P., Seyran, M., El‐Aziz, T. M. A., Rezaei, N., Lal, A., Aljabali, A. A. A., Kandimalla, R. J. L., et al. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102941 · Cited by 58
Esquivel‐Valerio, J. A., Skinner‐Taylor, C. M., Moreno-Arquieta, I. A., et al. (2021) · Rheumatology International · doi:10.1007/s00296-021-05017-9 · Cited by 58
IgA Nephropathy After SARS-CoV-2 Vaccination
Abramson, M. H., Yu, S. M.-W., Campbell, K. N., Chung, M., & Salem, F. E. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.05.002 · Cited by 57
Goldman, M., & Hermans, C. R. J. R. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003648 · Cited by 56
Talotta, R., & Robertson, E. S. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.05.001 · Cited by 52
Suresh, P., & Petchey, W. G. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-243931 · Cited by 52
Bonifacio, G., Patel, D., Cook, S., Purcaru, E., Couzins, M., Domjan, J., Ryan, S., Alareed, A. W., Tuohy, O., Slaght, S., et al. (2021) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-327027 · Cited by 51
Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines
Hwang, J., Lee, S. B., Lee, S. W., Lee, M. H., Koyanagi, A., Jacob, L., Tizaoui, K., Yon, D. K., Shin, J. I., & Smith, L. (2021) · Journal of Autoimmunity · doi:10.1016/j.jaut.2021.102681 · Cited by 45
IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19
Badier, L., Toledano, A., Porel, T., Dumond, S., Jouglen, J., Sailler, L., Bagheri, H., Moulis, G., & Lafaurie, M. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102951 · Cited by 45
Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination
Franchini, M., Testa, S., Pezzo, M. P., Glingani, C., Caruso, B., Terenziani, I., Pognani, C., Bellometti, S. A., & Castelli, G. P. (2021) · Thrombosis Research · doi:10.1016/j.thromres.2021.04.001 · Cited by 41
Autoimmune hepatitis following influenza virus vaccination
Sasaki, T., Suzuki, Y., Ishida, K., Kakisaka, K., Abe, H., Sugai, T., & Takikawa, Y. (2018) · Medicine · doi:10.1097/md.0000000000011621 · Cited by 40
Ntouros, P. A., Vlachogiannis, N. I., Pappa, M. B., Nezos, A., Mavragani, C. P., Tektonidou, M. G., Souliotis, V. L., & Sfikakis, P. P. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108765 · Cited by 40
Pierman, G., Delgrange, E., & Jonas, C. (2021) · European Journal of Case Reports in Internal Medicine · doi:10.12890/2021_002807 · Cited by 40
Immune thrombocytopenic purpura after SARS‐CoV‐2 vaccine
Candelli, M., Rossi, E., Valletta, F., Stefano, V. D., & Franceschi, F. (2021) · British Journal of Haematology · doi:10.1111/bjh.17508 · Cited by 39
Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination
Fueyo‐Rodríguez, O., Valente-Acosta, B., Jiménez-Soto, R., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242220 · Cited by 38
Is complement the culprit behind COVID-19 vaccine-related adverse reactions?
Mastellos, D. C., Skendros, P., & Lambris, J. D. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151092 · Cited by 35
Immune thrombocytopenic purpura and acute liver injury after COVID-19 vaccine
Hines, A., Shen, J. G., Olazagasti, C., et al. (2021) · BMJ Case Reports · doi:10.1136/bcr-2021-242678 · Cited by 33
MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets
Huang, C., Xing, X., Xiang, X., Fan, X., Men, R., Ye, T., & Yang, L. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110558 · Cited by 32
Cabanillas, B., Akdiş, C. A., & Novak, N. (2021) · Allergy · doi:10.1111/all.14725 · Cited by 30
A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
King, E., & Towner, E. (2021) · American Journal of Case Reports · doi:10.12659/ajcr.931478 · Cited by 30
Pulmonary embolism and thrombocytopenia following ChAdOx1 vaccination
Muster, V., Gary, T., Raggam, R. B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00871-0 · Cited by 29
Kreuter, A., Burmann, S., Burkert, B. A., Oellig, F., & Michalowitz, A. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17514 · Cited by 29
Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine
Julian, J. A., Mathern, D. R., & Fernando, D. (2021) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2021.02.011 · Cited by 28
Clinical features and prognostic factors of patients with COVID-19 in Henan Province, China
Zhang, Q., Wang, Z., Lv, Y., Zhao, J., Dang, Q., Xu, D., Zhao, D., Liu, H., Wang, Z., Zhao, X., et al. (2021) · Human Cell · doi:10.1007/s13577-021-00499-y · Cited by 26
Self-citationImmune Thrombocytopenic Purpura Following Pfizer-BioNTech COVID-19 Vaccine in an Elderly Female
Jasaraj, R. B., Shrestha, D. B., Gaire, S., & Kassem, M. A. (2021) · Cureus · doi:10.7759/cureus.16871 · Cited by 15
Acute immune thrombocytopenic purpura post first dose of COVID-19 vaccination
Wong, J. S. Y., Kang, J. H.-E., & Maw, K. Z. (2021) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2021-140947 · Cited by 11
COVID ‐19, Virchow's triad and thromboembolic risk in obese pregnant women
Carbillon, L., Fermaut, M., Benbara, A., & Boujenah, J. (2021) · Clinical Cardiology · doi:10.1002/clc.23602 · Cited by 5
Cited by
Lee, Y., Jeong, M., Park, J., Jung, H., & Lee, H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01086-x · Cited by 450
Risk of autoimmune diseases in patients with COVID-19: a retrospective cohort study
Chang, R., Yen-Ting Chen, T., Wang, S.-I., Hung, Y.-M., Chen, H.-Y., & Wei, C.-C. J. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2022.101783 · Cited by 308
Efe, C., Kulkarni, A. V., Terziroli Beretta‐Piccoli, B., Magro, B., Stättermayer, A., Cengiz, M., Clayton‐Chubb, D., Lammert, C., Bernsmeier, C., Gül, Ö., et al. (2022) · Hepatology · doi:10.1002/hep.32572 · Cited by 106
Histological and serological features of acute liver injury after SARS-CoV-2 vaccination
Codoni, G., Kirchner, T., Engel, B., Villamil, A. M., Efe, C., Stättermayer, A. F., Weltzsch, J. P., Sebode, M., Bernsmeier, C., Lleo, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2022.100605 · Cited by 37
Metadata
- Authors
- Chen, Y., Xu, Z., Wang, P., Li, X., Shuai, Z., Ye, D., & Pan, H.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2022-01-07
- Volume
- 165
- Issue
- 4
- Pages
- 386-401
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W4200092905
- Cited by
- 502
- References
- 108
- FWCI
- 30.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.